Skip to main content

Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy.

Publication ,  Journal Article
Misakian, AL; Ariel, D; Sullivan, EA; Singh, G; Loeb, D; Strickland, T; Iwamoto, SJ; Rothman, MS; Botzheim, B; Liang, JW; Kelley, C; Hamnvik, O-PR
Published in: Endocr Pract
November 2025

OBJECTIVE: To evaluate the association between injectable estradiol and serum total testosterone (TT) concentrations and determine additional associations between covariates (age, intramuscular vs subcutaneous administration, ester [cypionate vs valerate], injection timing relative to laboratory draw, antiandrogen use, and progestogen use) and TT concentration. METHODS: Cross-sectional retrospective multisite study including adult transgender and gender-diverse patients without a history of gonadectomy or concurrent gonadotropin-releasing hormone agonist use prescribed weekly injectable estradiol at a stable dose for >75 days between 2019 and 2023 with confirmed timing of estradiol and TT concentrations relative to last injection. Those who reached guideline-recommended TT suppression (<50 ng/dL) were compared with those who did not. A weighted linear mixed model evaluated relationship between TT concentration and covariates. RESULTS: Of the 357 patients included, the median estradiol dose, estradiol concentration, and TT concentration were 4 mg (interquartile range [IQR], 3-6 mg), 232 pg/mL (IQR, 134-371 pg/mL), and 17 ng/dL (IQR, 10-33 ng/dL), respectively. There was no significant difference in TT concentration or proportion reaching TT suppression between patients using estradiol monotherapy and estradiol with an antiandrogen(s) and/or a progestogen. In the weighted linear mixed model, higher estradiol concentration, fewer days since injection, and progestogen use were associated with a lower TT concentration. CONCLUSION: Injectable estradiol, even as monotherapy, was effective at TT suppression in 82.6% of patients and comparable with combination therapy with an antiandrogen(s) or progestogen. Progestogen use was independently associated with a lower TT concentration, whereas spironolactone had no significant effect.

Duke Scholars

Published In

Endocr Pract

DOI

ISSN

1530-891X

Publication Date

November 2025

Volume

31

Issue

11

Start / End Page

1462 / 1469

Location

United States

Related Subject Headings

  • Transgender Persons
  • Testosterone
  • Retrospective Studies
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Injections, Intramuscular
  • Humans
  • Gender-Affirming Procedures
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Misakian, A. L., Ariel, D., Sullivan, E. A., Singh, G., Loeb, D., Strickland, T., … Hamnvik, O.-P. (2025). Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy. Endocr Pract, 31(11), 1462–1469. https://doi.org/10.1016/j.eprac.2025.07.002
Misakian, Aaron L., Danit Ariel, Erika A. Sullivan, Gagandeep Singh, Danielle Loeb, Tyler Strickland, Sean J. Iwamoto, et al. “Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy.Endocr Pract 31, no. 11 (November 2025): 1462–69. https://doi.org/10.1016/j.eprac.2025.07.002.
Misakian AL, Ariel D, Sullivan EA, Singh G, Loeb D, Strickland T, et al. Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy. Endocr Pract. 2025 Nov;31(11):1462–9.
Misakian, Aaron L., et al. “Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy.Endocr Pract, vol. 31, no. 11, Nov. 2025, pp. 1462–69. Pubmed, doi:10.1016/j.eprac.2025.07.002.
Misakian AL, Ariel D, Sullivan EA, Singh G, Loeb D, Strickland T, Iwamoto SJ, Rothman MS, Botzheim B, Liang JW, Kelley C, Hamnvik O-PR. Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy. Endocr Pract. 2025 Nov;31(11):1462–1469.

Published In

Endocr Pract

DOI

ISSN

1530-891X

Publication Date

November 2025

Volume

31

Issue

11

Start / End Page

1462 / 1469

Location

United States

Related Subject Headings

  • Transgender Persons
  • Testosterone
  • Retrospective Studies
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Injections, Intramuscular
  • Humans
  • Gender-Affirming Procedures
  • Female